Literature DB >> 1683330

Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid.

S M Greenfield1, N A Punchard, R P Thompson.   

Abstract

The effects of sulphasalazine, 5-aminosalicylic acid (5-ASA), and sulphapyridine on peroxidation of red cell membrane lipids, measured as malondialdehyde production, were assessed. Sulphasalazine and 5-ASA, at concentrations of 10(-5)-10(-3) M significantly inhibit lipid peroxidation, suggesting an antioxidant action that may explain the efficacy of these drugs in treating inflammatory bowel disease. Sulphapyridine, which is not effective in inflammatory bowel disease inhibited malondialdehyde production at a concentration of 10(-3) M only.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683330      PMCID: PMC1379377          DOI: 10.1136/gut.32.10.1156

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  In vitro formation of activators for prostaglandin synthesis by neutrophils and macrophages from humans and guinea pigs.

Authors:  P J Marshall; W E Lands
Journal:  J Lab Clin Med       Date:  1986-12

2.  Toxic oxygen metabolite production by circulating phagocytic cells in inflammatory bowel disease.

Authors:  J G Williams; L E Hughes; M B Hallett
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

3.  5-Aminosalicylic acid, a co-factor for colonic prostacyclin synthesis?

Authors:  J R Hoult; H Page
Journal:  Lancet       Date:  1981-08-01       Impact factor: 79.321

4.  Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis.

Authors:  F Dallegri; L Ottonello; A Ballestrero; F Bogliolo; F Ferrando; F Patrone
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

5.  The effect of prostacyclin on the adhesion of leucocytes to injured vascular endothelium.

Authors:  G Jones; J V Hurley
Journal:  J Pathol       Date:  1984-01       Impact factor: 7.996

6.  Modulation of human colonic arachidonic acid metabolism by sulfasalazine.

Authors:  C J Hawkey; N K Boughton-Smith; B J Whittle
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

7.  Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine.

Authors:  M Ligumsky; F Karmeli; P Sharon; U Zor; F Cohen; D Rachmilewitz
Journal:  Gastroenterology       Date:  1981-09       Impact factor: 22.682

8.  The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger.

Authors:  I Ahnfelt-Rønne; O H Nielsen
Journal:  Agents Actions       Date:  1987-06

9.  Inhibition of prostaglandin synthetase in human rectal mucosa.

Authors:  C J Hawkey; M Lo Casto
Journal:  Gut       Date:  1983-03       Impact factor: 23.059

10.  Measurement of lipid peroxidation in vivo: a comparison of different procedures.

Authors:  A Pompella; E Maellaro; A F Casini; M Ferrali; L Ciccoli; M Comporti
Journal:  Lipids       Date:  1987-03       Impact factor: 1.880

View more
  8 in total

1.  Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease.

Authors:  A Keshavarzian; A Banan; A Farhadi; S Komanduri; E Mutlu; Y Zhang; J Z Fields
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 2.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

3.  Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor alpha: a novel mechanism of action of sulphasalazine.

Authors:  S M Greenfield; A S Hamblin; Z S Shakoor; J P Teare; N A Punchard; R P Thompson
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

Review 4.  Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.

Authors:  Nielsen Q Fernandez-Becker; Alan C Moss
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Resistance of erythrocytes to lipid peroxidation in alcoholic patients.

Authors:  N A Punchard; H Senturk; J P Teare; R P Thompson
Journal:  Gut       Date:  1994-12       Impact factor: 23.059

Review 6.  Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.

Authors:  A Prakash; A Markham
Journal:  Drugs       Date:  1999-03       Impact factor: 11.431

Review 7.  Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications.

Authors:  Daniel Fernández-Villa; Maria Rosa Aguilar; Luis Rojo
Journal:  Int J Mol Sci       Date:  2019-10-09       Impact factor: 5.923

8.  Mechanism of action of 5-arninosalicylic acid.

Authors:  N A Punchard; S M Greenfield; R P Thompson
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.